Abstract: Chemotherapy is an important cancer treatment method. Tumor chemotherapy resistance is one of the main factors leading to tumor progression. Like other malignancies, bladder cancer, especially muscle-invasive bladder cancer, is prone to chemotherapy resistance. Additionally, only approximately 50% of muscle-invasive bladder cancer responds to cisplatinbased chemotherapy. miRNAs are a class of small, endogenous, noncoding RNAs that regulate gene expression at the posttranscriptional level, which results in the inhibition of translation or the degradation of mRNA. In the study of miRNAs and cancer, including gastric cancer, prostate cancer, liver cancer, and colorectal cancer, it has been found that miRNAs can regulate the expression of genes related to tumor resistance, thereby promoting the progression of tumors. In bladder cancer, miRNAs are also closely related to chemotherapy resistance, suggesting that miRNAs can be a new therapeutic target for the chemotherapy resistance of bladder cancer. Therefore, understanding the mechanisms of miRNAs in the chemotherapy resistance of bladder cancer is an important foundation for restoring the chemotherapy sensitivity of bladder cancer and improving the efficacy of chemotherapy and patient survival. In this article, we review the role of miRNAs in the development of chemotherapy-resistant bladder cancer and the various resistance mechanisms that involve apoptosis, the cell cycle, epithelial-mesenchymal transition (EMT), and cancer stem cells (CSCs).
which leads to the relapse and progression of tumors. Therefore, overcoming multidrug resistance and exploring a novel safe and effective treatment strategy is urgently needed for BCa, especially MIBC.
Recent research has indicated that posttranscriptional regulatory mechanisms play a crucial role in various tumor biological properties, including chemotherapy resistance, and the most important molecules involved include miRNAs and human antigen R. 7, 8 miRNAs are a class of endogenous small noncoding RNAs that are approximately 18-25 nt in length and were first discovered in 1993. 9 Since their discovery, an increasing number of miRNAs have been identified. miRNAs recognize and bind to the 3ʹ-untranslated region (3ʹ-UTR) of target mRNAs with complete or incomplete complementary pairs and cause the degradation of the target mRNA or the inhibition of translation, thereby negatively regulating the expression of cancer-related molecules. 10 Studies have revealed that nearly one-third of human genes, including those involved in tumor development, angiogenesis, invasion, metastasis and drug resistance, can be regulated by miRNAs. Therefore, miRNAs act as oncogenes or tumor suppressor genes, depending on their complex regulatory mechanisms.
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In recent years, tumor-related studies have shown that miRNAs are involved in the biological properties of BCa, including chemoresistance. Based on their important roles in BCa, miRNAs have been widely studied as therapeutic targets for BCa treatment. This paper will review the role of miRNAs in the chemoresistance of BCa and explore the related targeted therapeutic strategies.
Expression Patterns of Chemoresistance-Related miRNAs in BCa
Dysregulated expression of miRNAs in tumors involves pathophysiological processes. 12, 13 With the development of microarray analysis methods, real-time polymerase chain reaction (RT-PCR) and bioinformatic techniques, numerous cancer-related miRNAs have been discovered, most of which are closely associated with chemoresistance in many tumors, including BCa. [14] [15] [16] [17] The 5637 cell line is the most multichemosensitive cell line of the BCa cell lines (5637, T24, EJ, H-bc and Biu87), and H-bc is the most resistant cell line. An RNA-seq-based miRomic analysis of the 5637 and H-bc cell lines showed that 83 miRNAs were differentially expressed by at least twofold (37 were more highly expressed and 45 were less highly expressed in the 5637 cells than in the H-bc cells). 18 Microarray analysis of gemcitabine-resistant and parental cells revealed 66 differentially expressed miRNAs, including 41 miRNAs and 25 unidentified human miRPlus sequences in the miRBase database. 19 Among these differentially expressed miRNAs, miR-1290 and miR-138 showed increased expression levels in gemcitabine-resistant cells, while let-7b and let7i exhibited decreased expression. 18, 19 Transfection of pre-miR-138 and pre-miR-1290 into parental cells attenuated gemcitabine-induced cell death, while transfection of pre-miRlet-7b and pre-miR-let-7i into the resistant cells augmented cell death. 18, 19 
miRNA-Mediated Pathways in the Chemoresistance of BCa
In terms of mechanisms, accumulating studies have revealed that miRNAs regulate the chemoresistance of BCa through a variety of signaling pathways. Current research indicates that the signaling pathways involving miRNAs are related to the following aspects:
Regulation of Cell Apoptosis
Apoptosis is one of the most important mechanisms by which multicellular organisms respond to environmental changes and maintain tissue homeostasis. [39] [40] [41] Recent studies have shown that miRNAs play a key role in regulating apoptosis and its relationship with chemoresistance in BCa. miRNAs mediate chemoresistance in BCa by regulating the expression of members of the Bcl-2 family. Zhan et al 24 showed that overexpression of miR-203 enhanced cisplatin sensitization by promoting apoptosis by directly targeting Bcl-w and survivin. Survivin is a key member of the inhibitor of apoptosis protein (IAP) family and exerts its antiapoptotic function by blocking caspase activity in a complex with the X-linked inhibitor of apoptosis protein (XIAP). 42 In addition, studies have demonstrated that miR-133b regulates the proliferation and apoptosis of BCa cells (T24) by targeting Akt and Bcl-w. 43 In BCa cells, Bcl-2 is regulated by miR-21, miR-192, miR-221, miR-9, miR-675, miR-29c, and Mcl-1 and is regulated by miR-192 and miR-29c. [44] [45] [46] [47] [48] [49] These miRNAs mediate the proliferation and apoptosis of BCa cells by regulating the expression of members of the Bcl-2 family. We speculate that the above miRNAs also play an important role in the chemotherapy resistance of BCa. The PTEN/PI3K/Akt/mTOR signaling pathway plays a key role in the progression of BCa. The roles of Akt in cells are diverse, but all of the roles lead to antiapoptosis or cell proliferation. It is well known that the PI3K/Akt oncogenic signaling pathway is activated in response to various growth factors and extracellular matrix (ECM) proteins. 50 59 The insulin-like growth factor-1 receptor (IGF-1R) and its ligand play an important role in regulating cell proliferation and apoptosis. The combination of IGF-1R and its ligand triggers the downstream PI3K/Akt signaling pathway (Figure 2 ). Wang et al showed that miR-143 can target IGF-1R and promote the chemosensitivity of BCa cells (5637) to gemcitabine. 29 
Regulation of the Cell Cycle
With advancements in our understanding of the basic mechanisms of tumor-related processes, cell cycle physiology, and apoptosis mechanisms, it is becoming increasingly apparent that the cell cycle plays a key role in chemosensitivity, especially sensitivity to combined chemotherapy. 60 Recent studies have shown that miRNAs participate in the processes related to cell cycle-related chemoresistance in BCa. Increased miR-34a expression levels have been found to promote the chemosensitivity of BCa cell lines to cisplatin treatment by targeting CDK6 and SIRT-1. 61 However, the inhibition of CDK6 and SIRT-1 was not as effective as the inhibition of pre-miR-34a in mediating chemosensitization. We speculate that this difference lies in the fact that miRNAs can simultaneously regulate multiple target genes, indicating that targeting these miRNAs may be more effective than targeting a single chemoresistance-related gene. UCA1, a class of lncRNAs, activates the transcription factor CREB, which leads to the expression of miR-196a-5p by binding with its promoter. miR-196a-5p is involved in the inhibition of apoptosis by UCA1 that is induced by cisplatin/gemcitabine by targeting p27. 27 These data suggest that the mechanisms of miRNA-mediated chemosensitivity involve a complex network system, that the novel lncRNA/miRNA/target gene axis plays an important role in tumor therapy and that any component of the axis can serve as a tumor treatment target. In addition, HOX gene family member-HOXC9 as an oncogene and a novel miR-193a-3p target has also been found to exert a promoting effect of miR-193a-3p in BCa chemoresistance. HOXC9 has been reported to bind to and activate the expression of a large number of genes involved in the DNA damage response, such as TP53 and E2F6. 62 Therefore, the miR-193a-3p/HOXC9/DNA damage response axis plays a key role in the chemoresistance of BCa. We found that the role of miRNAs depends on complex network axes and that an increasing number of upstream regulatory genes as well as downstream targets are involved. We hypothesize that the therapeutic effect of targeting upstream genes is superior to that of targeting downstream genes; however, complex network regulation axes still require further investigation. Studies have demonstrated that miRNAs mediate cell cycle-regulated chemoresistance by targeting CDK and p27. We also summarized that these miRNAs, including miR-29c, miR-124, miR-449a, miR320c, miR-106a, miR-20b, and miR-195, can target CDK. [63] [64] [65] [66] [67] [68] [69] In addition, miR-221 and miR-192 can target p27. 70 The roles of most miRNAs in the chemoresistance of BCa have not been studied, although these miRNAs can regulate the biological characteristics of BCa, which is one of the directions to be explored in the future. 
Tumor Stem Cells
Stem cells are undifferentiated cells that have the ability to self-renew while producing differentiated tissues or organspecific cells by asymmetric cell division. Knowledge of the importance of stem cells in normal tissue biology has led to the belief that cancer may also come from a pool of progenitor cells (the cancer stem cell (CSC) hypothesis). CSCs are a subpopulation of cancer cells responsible for tumor initiation, differentiation, recurrence, metastasis and drug resistance. [71] [72] [73] CSCs can be isolated from a large number of tumor cells based on characteristic cell surface markers, such as CD44 and CD133. CD44 is also described as a marker for bladder CSCs that are resistant to therapeutic drugs. 74, 75 CD44 is targeted by miR-34a in MIBC cells after cisplatin treatment, and increased expression of CD44 could effectively reverse the effects of miR-34a on the proliferation, cloning potential and chemosensitivity of MIBC cells. 76 The mechanism by which CSCs are involved in chemoresistance may be related to the fact that they produce drug-resistant daughter cells under the pressure of drug action. However, the exact mechanism remains unclear.
Epithelial-Mesenchymal Transition
Epithelial-mesenchymal transition (EMT) is a process that plays major roles in development and wound healing and is characterized by the loss of homotypic adhesion and cell polarity and increased invasion and migration. At the molecular level, EMT is characterized by the loss of E-cadherin and the increased expression of several transcriptional repressors of E-cadherin expression (ZEB1, ZEB2, Twist, Snail, and Slug). 77, 78 Studies have shown that EMT is involved in the resistance of a variety of cancer drug treatments [79] [80] [81] [82] and is regulated by multiple signaling pathways. 83, 84 In BCa, the stable expression of miR-200 in mesenchymal UMUC3 cells increases E-cadherin levels; decreases the expression of ZEB1, ZEB2 and the tumor suppressor gene ERRFI-1 and cell migration; and increases EGFR blocker sensitivity. 22 In addition, it has been shown that ERRFI-1 can be targeted by miR-200. 22 The differential expression of the following miRNAs in BCa is associated with the EMT process: miR-433, miR-323a-3p, miR-22, miR-92, miR-96, miR-199a-5p, miR-301b, miR-613, miR-370-3p and miR-451. [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] These miRNAs are associated with BCa cell proliferation, migration, invasion and EMT. For instance, miR-433 targets c-Met and CREB1 and inhibits EMT in BCa cells by modulating the c-Met/Akt/GSK-3β/Snail signaling pathway. 85 miR-323a-3p regulates the EMT progression of BCa by targeting c-Met and SMAD3 and by negatively regulating their expression by modulating the c-Met/SMAD3/Snail pathway. 86 In addition, the overexpression of miR-613 enhanced the expression of the epithelial biomarker E-cadherin and inhibited the expression of mesenchymal biomarkers (vimentin, Snail and N-cadherin). 92 Moreover, sphingosine kinase 1 (Sphk1), as an oncogene, promotes tumor cell survival by converting ceramide to sphingosine and has been identified as a direct target gene of miR-613 in BCa cells. 92 The recovery of Sphk1 partially reversed the inhibition of the proliferation, invasion and EMT of BCa cells induced by miR-613. Therefore, miR-613 exerts a tumor suppressive effect in BCa by targeting Sphk1. The Notch pathway has a negative regulatory effect on EMT, and DNA methylation in BCa regulates the high expression of mir-193a-3p, thus inhibiting the Notch pathway to promote EMT-induced multidrug resistance. 18, 95 Figure 3 shows the miRNAs associated with BCa EMT as well as their target genes and the EMT regulatory pathways.
Other Pathways
Generally, the chemoresistance of tumors involves complex networks. Mechanisms of multidrug resistance have been the subject of a great amount of research. In addition to the abovementioned signaling pathways, miRNAs can also regulate chemoresistance through other novel signaling pathways. Low expression of miR-101 induced cell survival and cisplatin resistance by negatively regulating COX-2 expression. 21 In addition, COX-2 was also shown to be Figure 3 In BCa, these miRNAs regulate the EMT process. 101 and is a novel tumor-associated gene associated with many malignancies through multiple regulatory mechanisms. [102] [103] [104] [105] Finally, overexpression of miRNA27a has been reported to be associated with reduced levels of SLC7A11 and the intracellular levels of glutathione and to cause resistant cells to become resensitized to cisplatin. 34 Notably, the tumor microenvironment, including the extracellular matrix and stromal cells, is closely related to the increase in drug resistance. 106 Stromal cells, such as macrophages and fibroblasts, can produce growth factors to change the characteristics of tumor cells and increase drug resistance. 106 Interactions between the tumor microenvironment and tumor, as well as the interior of the microenvironment, are mediated by important signal molecules. As an important signal molecule, miRNA levels are closely related to the tumor microenvironment. In BCa, it has been shown that tumor-related macrophages can promote EMT by increasing miR-30a levels, 107 and EMT is one of the important mechanisms of drug resistance in BCa. Although there is limited evidence of the relationship between the tumor microenvironment and miRNA levels in BCa, this is an important direction and deserves further study.
Conclusions
Tumor-related research has evolved from studying a single oncogene or tumor suppressor gene to developing the current network regulation axis model. Changes in various biological properties of tumors, including the development of chemoresistance, are closely related to the dysregulation of miRNAs. lncRNAs, circRNAs and RNA-binding proteins are involved in the regulation of miRNA expression. The lncRNA/ miRNA/target gene axis, the circRNA/miRNA/target gene axis, the RBP/miRNA/target gene axis, etc., constitute a complex tumor regulatory network. miRNAs may be the core factor, and the therapeutic effect of targeting miRNAs may be more effective than the effect of targeting a single oncogene. In tumors, miRNAs are involved in a variety of chemoresistance-related signaling pathways to regulate tumor resistance. Currently, miRNA-based therapeutic strategies include the use of agomir-miRNA, miR-101 mimic, and miRNA inhibitors. Extensive cell experiments have demonstrated the potential of these strategies to reverse chemoresistance in chemotherapy. miRNAs also have potential value in the treatment of chemotherapy resistance in BCa. In addition, the bladder is a smooth-muscle organ with an independent cavity that can be treated by perfusion administration, which greatly reduces targeting and safety problems. Therefore, miRNA-targeted therapy strategies to treat BCa chemotherapy resistance are a very promising treatment direction. Unfortunately, there are still many components of miRNA-targeted therapy strategies that need to be further elucidated. For example, how many miRNAs are associated with BCa resistance? Which miRNA is the most important? What duration of miRNA targeting is required to regulate drug resistance? Research on these issues will demonstrate the utility of miRNA-targeted therapeutic strategies and lay the foundation for further clinical trials.
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